Morning, Tuesday, 17th April 2018
The Caledonian Club, 9 Halkin Street, London SW1X 7DR
THIS EVENT IS CPD CERTIFIED
This conference considers the future for regenerative medicine, advanced therapies and stem cell research - examining key issues for the UK’s research infrastructure, regulatory environment and appraisal processes, as well as the challenges for responding to Brexit.
Delegates will assess the potential impact of key recommendations from the Life Sciences Sector Deal and the Life Sciences Industrial Strategy - which included implementing the Medicines Manufacturing Industry Partnership’s Advanced Therapies Manufacturing Action Plan in full and increasing investment in ‘moonshot’ research programmes through a Health Advanced Research Programme.
They will also consider the impact of additional funding for biomedical research, as £1 million will be made available for ‘regenerative medicine at the front line’ via a Defence and Security Accelerator competition being held by the Government.
Further sessions will discuss the Government’s response to the Commons Science and Technology Committee inquiry into Regenerative Medicine, which focused on the challenges for increasing the adoption of advanced therapies in the NHS - and called for the introduction of a fast-track appraisal process, the creation of new reimbursement payment models and the alignment of policy with the development of a personalised and genomic medicine strategy.
Attendees will also discuss opportunities for aligning the regulatory work of NICE and MHRA through a ‘one-stop shop’, as well as the challenges for implementing the Government response to the Accelerated Access Review, addressing ethical concerns and developing a new relationship with EU regulatory bodies on Advanced Therapy Medicinal Products.